Tokyo-based Elix (founded 2016) has launched Elix Discovery, an AI drug discovery platform powered by federated learning models trained on proprietary compound data from 16 pharmaceutical companies. The platform is the first commercial deployment to result from Japan’s AMED-backed DAIIA initiative (2020–2025), which brought together 17 pharma companies and institutions including RIKEN, Kyoto University, and Nagoya University.
The core technical framework—kMoL—was developed with Kyoto University’s…
